Original Source(s)
Related Content
FDA Expands Guselkumab Label in PsA
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
May 29, 2026
-
2 min
Wearables May Boost T2D Mobility
Outpatient intervention combined physiotherapist counseling with wrist-worn activity monitoring.
May 11, 2026
-
4 min
RA Outcomes Improved in KURAMA Cohort
Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.
May 22, 2026
-
4 min
